ANS Pharmacology: Anticholinergic Drugs and Management of Poisoning

Introduction

Anticholinergic agents constitute a pharmacologic class that antagonises the action of acetylcholine at muscarinic and nicotinic receptors. The resulting blockade of cholinergic signalling manifests as a constellation of signs and symptoms collectively referred to as the anticholinergic toxidrome. Understanding the pharmacodynamics, pharmacokinetics, and therapeutic applications of these compounds is paramount for clinicians and pharmacists, particularly in the context of acute poisoning where timely intervention can be life‑saving.

Historically, the discovery of atropine in the 18th century by Herman Boerhaave marked the beginning of anticholinergic therapy. Subsequent identification of scopolamine, hyoscine, and a multitude of synthetic derivatives expanded the therapeutic arsenal for gastrointestinal motility disorders, postoperative nausea, and ophthalmologic procedures. Over the past century, anticholinergic drugs have also been employed in the management of neuropsychiatric conditions, such as Parkinson’s disease, Tourette syndrome, and certain forms of epilepsy. The widespread use of these agents has necessitated a robust framework for recognising and treating anticholinergic overdose.

Learning objectives for this chapter include:

• Describe the pharmacologic basis of anticholinergic action.
• Identify the key receptor subtypes and their distribution.
• Analyse the clinical manifestations of anticholinergic toxicity.
• Outline evidence‑based management strategies for acute poisoning.
• Apply pharmacologic principles to case‑based scenarios.

Fundamental Principles

Core Concepts and Definitions

Anticholinergics are defined as compounds that inhibit the binding of acetylcholine to its receptors or impair downstream signalling pathways. The primary targets are muscarinic acetylcholine receptors (mAChRs), of which five subtypes (M1–M5) exist, each with distinct anatomical and functional profiles. Nicotinic acetylcholine receptors (nAChRs), located at the neuromuscular junction and autonomic ganglia, are also susceptible to blockade, though most clinically relevant anticholinergics preferentially target muscarinic sites.

Theoretical Foundations

The pharmacologic effect of an anticholinergic agent can be conceptualised via the receptor occupancy model. The fraction of receptors bound (θ) is expressed as:

θ = [D] / ([D] + K_d)

where [D] denotes the drug concentration at the receptor site and K_d is the equilibrium dissociation constant. Increases in [D] or decreases in K_d enhance receptor occupancy, thereby intensifying the pharmacologic response. The maximal effect (E_max) is approached as θ approaches unity, assuming a purely competitive antagonist with no intrinsic activity.

Beyond simple occupancy, the functional antagonism of acetylcholine is modulated by the intrinsic activity of the ligand, receptor reserve, and downstream signalling amplification. These factors collectively influence the dose‑response relationship, which is often sigmoid and can be described by the Hill equation:

E = E_max × [D]ⁿ / (EC₅₀ⁿ + [D]ⁿ)

where n represents the Hill coefficient, indicating cooperativity.

Key Terminology

• Anticholinergic Toxidrome – Clinical syndrome resulting from excessive muscarinic blockade, characterised by dry mouth, dilated pupils, tachycardia, urinary retention, hyperthermia, and altered mental status.
• Muscarinic Receptor Subtypes – M1 (central and glandular), M2 (cardiac), M3 (smooth muscle and glands), M4 (central), M5 (vascular).
• Intrinsic Activity – The ability of a ligand to elicit a response independent of endogenous agonist.
• Receptor Reserve – Quantity of spare receptors available to produce a maximal response.

Detailed Explanation

Mechanisms of Anticholinergic Action

At the molecular level, anticholinergic drugs act as competitive antagonists at muscarinic receptors, occupying the orthosteric binding site and preventing acetylcholine from eliciting a signal. This inhibition leads to decreased stimulation of G_q and G_i pathways, thereby attenuating intracellular calcium mobilisation and cyclic AMP production. The net effect is a reduction in parasympathetic tone, manifested as decreased secretions, slowed gastrointestinal motility, and diminished autonomic reflexes.

In addition to direct receptor blockade, certain anticholinergics exhibit functional antagonism by modulating downstream effectors. For instance, blockade of M3 receptors on airway smooth muscle reduces muscarinic‑mediated bronchoconstriction, a property exploited in the treatment of chronic obstructive pulmonary disease (COPD). Conversely, the absence of receptor activation can indirectly influence central neurotransmission, as seen in the antipsychotic properties of some anticholinergic agents.

Pharmacokinetics and Factors Affecting Bioavailability

Absorption of anticholinergic agents is largely dependent on chemical structure and formulation. Oral bioavailability ranges from 10–90%, influenced by first‑pass metabolism and gastrointestinal pH. Lipophilic compounds (e.g., atropine) readily cross the blood‑brain barrier, whereas hydrophilic molecules (e.g., glycopyrrolate) are largely excluded from central nervous system (CNS) penetration. This differential distribution underpins the variable CNS toxicity profiles among anticholinergics.

Distribution is governed by plasma protein binding; highly bound drugs (e.g., scopolamine) exhibit a large volume of distribution, facilitating tissue sequestration. Metabolism predominantly occurs in the liver via phase I oxidative reactions (CYP450 enzymes) and phase II conjugation, with subsequent renal or biliary excretion. Renal impairment prolongs drug half‑life, increasing the risk of accumulation, particularly in the elderly.

Mathematical Relationships in Anticholinergic Toxicity

Quantitative bedside assessment of anticholinergic load has been attempted using the Anticholinergic Cognitive Burden (ACB) scale, which assigns weighted scores to individual drugs based on receptor selectivity and CNS penetration. The cumulative ACB score can be used as a surrogate for predicting cognitive decline and delirium risk, though validation remains limited.

Serum concentration–effect relationships have been described for atropine, with a threshold of 1–2 ng/mL correlating with onset of central toxicity. However, inter‑individual variability necessitates clinical correlation rather than reliance on absolute concentrations.

Clinical Significance

Relevance to Drug Therapy

Anticholinergic drugs remain integral to the management of several therapeutic domains. In gastroenterology, atropine and hyoscine are employed to reduce splanchnic blood flow and relieve spasm. Ophthalmology utilises tropicamide and phenylephrine for pupil dilation. Neurology and psychiatry benefit from the antimuscarinic properties of certain antipsychotics and antiepileptic agents. Additionally, the bronchodilatory effect of anticholinergics is exploited in COPD management.

From a pharmacotherapeutic standpoint, anticholinergic burden is increasingly recognised as a contributor to adverse drug events, particularly in geriatric populations. Excessive anticholinergic exposure correlates with falls, cognitive impairment, and increased mortality risk. Therefore, judicious use and monitoring are advocated.

Practical Applications

Clinical guidelines recommend routine assessment of anticholinergic load in patients on polypharmacy regimens. Drug‑specific strategies include:

• Replacing high‑burden agents with lower‑burden alternatives (e.g., switching from diphenhydramine to cetirizine).
• Implementing dose‑reduction protocols based on renal function.
• Educating patients on signs of CNS toxicity (e.g., delirium, visual disturbances).

Clinical Examples

Case 1: A 72‑year‑old man on multiple antihistamines presents with confusion and mydriasis. A review of his medication list reveals an anticholinergic burden score of 6/9, suggesting a high risk of central toxicity. Discontinuation of the offending agents and administration of intravenous fluids lead to clinical improvement.

Case 2: A 35‑year‑old woman with severe COPD is prescribed tiotropium (a long‑acting anticholinergic). She develops dry mouth and urinary retention, prompting dose adjustment and counselling regarding symptom monitoring.

Clinical Applications/Examples

Case Scenarios Involving Anticholinergic Overdose

Clinical suspicion of anticholinergic poisoning is often raised by the triad of dry mucous membranes, dilated pupils, and tachycardia. Recognising the full toxidrome—hyperthermia, urinary retention, delirium, and ataxia—is essential for prompt intervention. The following scenarios illustrate common presentations and management strategies.

1. Scenario A: Acute Overdose with Atropine
   • Presentation: Severe agitation, blurred vision, tachycardia, hyperthermia.
   • Management: Establish airway and breathing; administer activated charcoal if within 1 h of ingestion; consider intravenous benzodiazepines for agitation; monitor cardiac rhythm for arrhythmias.
2. Scenario B: Chronic Exposure in Elderly
   • Presentation: Persistent confusion, falls, urinary retention.
   • Management: Comprehensive medication review; deprescribe high‑burden anticholinergics; implement fall‑prevention protocols.
3. Scenario C: Poisoning with Scopolamine (The “Devil’s Breath”)
   • Presentation: Hyperthermia, tachycardia, seizures, hallucinations.
   • Management: Aggressive cooling measures; anticonvulsants; consider use of physostigmine (an anticholinesterase) if severe CNS depression is present, with caution due to potential for bradycardia and seizures.

Problem‑Solving Approaches

When confronted with suspected anticholinergic toxicity, a systematic approach is advisable:

• Step 1: Confirm history and identify potential sources (over-the-counter, prescription, or illicit).
• Step 2: Assess vital signs and organ systems (cardiovascular, neurological, respiratory).
• Step 3: Initiate supportive care—airway management, oxygenation, intravenous fluids.
• Step 4: Consider specific antidotes (physostigmine) only after evaluating contraindications and monitoring for adverse effects.
• Step 5: Monitor for complications such as seizures, arrhythmias, and hyperthermia; employ cooling blankets or ice packs as needed.

Summary / Key Points

• Anticholinergic drugs antagonise muscarinic acetylcholine receptors, leading to a cascade of peripheral and central effects.
• Receptor subtype distribution explains the diverse therapeutic indications and toxicity profiles of anticholinergic agents.
• Pharmacokinetic parameters—including absorption, distribution, metabolism, and excretion—are critical determinants of both efficacy and risk of accumulation.
• The anticholinergic toxidrome is characterised by dry mucous membranes, mydriasis, tachycardia, hyperthermia, agitation, and urinary retention.
• Management prioritises supportive care, seizure control, arrhythmia monitoring, and judicious use of physostigmine as an antidote.
• Regular assessment of anticholinergic burden, especially in older adults, can mitigate adverse events and improve clinical outcomes.

Careful integration of pharmacologic principles with clinical vigilance remains essential for the effective utilisation of anticholinergic drugs and the management of their associated poisoning scenarios.

References

1. Klaassen CD, Watkins JB. Casarett & Doull's Essentials of Toxicology. 3rd ed. New York: McGraw-Hill Education; 2015.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
6. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.